semaglutide naion linked to increased risk of severe eye condition in new study Is Semaglutide Linked to NAION?
Description
Growing Scientific Interest
Important Notice: For laboratory research purposes only
Today our partner Amylyx Pharmaceuticals shared exciting news: the nomination of AMX0318 as a development candidate - a novel, long-acting GLP-1 receptor antagonist identified through our collaboration
Discover what UK clinical evidence reveals about semaglutide and rectal bleeding, when to seek urgent medical advice, and how to manage gastrointestinal side effects safely.
Notably, no permanent treatment discontinuations or dose reductions due to gastrointestinal side effects were reported in ribupatide-treated participants
